Isoliquiritigen enhances the antitumour activity and decreases the genotoxic effect of cyclophosphamide. 2013

Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
School of Pharmacy, Shihezi University, Shihezi 832002, China.

The aim of this study was to evaluate the antitumour activities and genotoxic effects of isoliquiritigenin (ISL) combined with cyclophosphamide (CP) in vitro and in vivo. U14 cells were treated with either of ISL (5-25 μg/mL) or CP (0.25-1.25 mg/mL) alone or with combination of ISL (5-25 μg/mL) and CP (1.0 mg/mL) for 48 h. The proliferation inhibitory effect in vitro was evaluated by MTT and colony formation assays. KM mice bearing U14 mouse cervical cancer cells were used to estimate the antitumour activity in vivo. The genotoxic activity in bone marrow polychromatic erythrocytes was assayed by frequency of micronuclei. The DNA damage in peripheral white blood cells was assayed by single cell gel electrophoresis. The results showed that ISL enhanced antitumour activity of CP in vitro and in vivo, and decreased the micronucleus formation in polychromatic erythrocytes and DNA strand breaks in white blood cells in a dose-dependent way.

UI MeSH Term Description Entries
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones

Related Publications

Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
April 2006, Basic & clinical pharmacology & toxicology,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
January 1982, British journal of cancer,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
December 1982, The Japanese journal of experimental medicine,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
January 1986, Archivum immunologiae et therapiae experimentalis,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
September 2002, Cancer chemotherapy and pharmacology,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
December 2018, Journal of cellular and molecular medicine,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
March 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
January 2017, Bratislavske lekarske listy,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
July 2005, International immunopharmacology,
Hong Zhao, and Xuan Yuan, and Defang Li, and Hongmei Chen, and Jiangtao Jiang, and Zhiping Wang, and Xiling Sun, and Qiusheng Zheng
January 1997, International journal of cancer,
Copied contents to your clipboard!